News|Articles|September 12, 2024

Assessing the Relationship Between C-diff Risk and Antibiotic Exposure

C diff remains a major healthcare burden globally, with over 225,000 hospitalizations in the US alone. Over half of these cases had recent antibiotic exposure, underlining the significant relationship between antibiotic use and the risk of the healthcare-associated infection.

With surging COVID-19 cases, an ongoing H5N1 outbreak, and a global health emergency related to mpox, we’ve got a number of infectious diseases challenges to face. In truth, that’s just the tip of the iceberg. Of these public health threats, there are some that are frequently neglected, healthcare-associated infections, antimicrobial resistance, and Clostridioides difficile (C difficile).

C difficile in particular is one that has challenged healthcare infection prevention efforts and can be deeply impactful for patients. The Centers for Disease Control and Prevention (CDC) recently reported that in 2022, the incidence rates of C difficile infection (CDI) increased with age and rates were higher in women. Moreover, there were 116 cases per 100,000 persons reported in surveillance sites, with 56% of cases having used antibiotics in the 12 weeks prior to infection.1

As the leading cause of healthcare-associated diarrhea globally and causes over 225,000 hospitalizations within the United States alone, CDI is a significant public health burden. Moreover, CDI represents an important aspect of antimicrobial stewardship given that recent exposure to certain classes of antibiotics has shown to increase risk.

As we work to understand the risk factors and transmission dynamics for CDI, so much points to the significance of recent antibiotic use and/or presence in a healthcare facility. How does transmission work in relation to exposure to high CDI-risk antibiotics and in what way is colonization impacted? In light of these variables, a new study has been published in PLoS One regarding the underlying mechanisms for assessing relative risk of CDI in those hospitalized patients with antibiotic exposure.2

What You Need to Know

These infections are increasing, especially with age and in women, as reported by the CDC in 2022.

The study in PLoS One highlights the importance of antimicrobial stewardship programs. By reducing antibiotic use, especially high-risk antibiotics, healthcare facilities can decrease both the rate of acquiring C. difficile and the progression from colonization to infection.

The deterministic model used in the study helped explore how antibiotic exposure affects CDI risk in hospitalized patients. It was found that targeted stewardship interventions—like shifting from high- to low-risk antibiotics—can reduce infection rates.

Using a deterministic model to understand the relationship and risk ratio of CDI in those patients with and without antibiotic exposure, the researchers sought to then calculate the sensitivity of potential antimicrobial stewardship intervention impacts. The goal was really to understand how acquiring C difficile (and progression of disease) is impacted by antimicrobial exposure. The authors delved into transmission dynamic models comparing antibiotic exposure outcomes to risk, noting how patients can transition from elevated to no elevated risk, but also a compartment model in which patients were either susceptible, colonized, or infected.

The authors found that, “the impact of 2 antibiotic stewardship interventions on facility acquisition and progression from colonization is as expected, by decreasing the overall antibiotic prescribing rate both the rate of acquisition and the rate of progression to CDI decrease.” Interestingly, when exploring the potential impact of shortening the duration that high-risk antibiotics were given, they found that “that the facility-onset acquisition rate and the facility-onset progression are both increased” and that when shifting prescriptions from high to low risk antibiotic classes, the impact “decreases both the rate of facility-onset infections and colonizations.”

Ultimately, this study points to the need for additional research and data to harness modeling power as we learn more about the role of stewardship programs and CDI within hospitalized patients. The authors note that the effects of stewardship interventions are “sensitive to their assumed values,” drawing attention to the impact of assumptions in these models and our overall understanding of these dynamics.

In short, it is vital that we invest more resources into understanding CDI infections, transmission, and the role of antimicrobial stewardship interventions.

References
1.Clostridioides difficile Infection (CDI) Surveillance. CDC. 2024. June 26, 2024. Accessed September 11, 2024.
https://www.cdc.gov/healthcare-associated-infections/php/haic-eip/cdiff.html
2.Mitchell C, Keegan LT, Le TTT, et al. Importance of underlying mechanisms for interpreting relative risk of Clostridioides difficile infection among antibiotic-exposed patients in healthcare facilities. PLoS One. 2024;19(8):e0306622. Published 2024 Aug 8. doi:10.1371/journal.pone.0306622


Related to this article

Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Ebola and the Ongoing Tale of US Failures
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.